US patent approval related to Episealer® Talus for Episurf Medical
Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent, entitled “Surgical Kit for Repair of Articular Surfaces in the Talocrural Joint Including Surgical Saw Guide”, covers Episurf Medical’s ankle implant Episealer® Talus and related surgical tools including a novel osteotomi guide for surgical access to the difficult to reach talar bone. This is the first approval in this patent family.
"Episurf’s implant technology has been adapted to the ankle joint through the development of Episealer® Talus. We already have IP protection for the Episealer® Talus technology. However, access to the talus bone is a specific challenge in treatment of ankle lesions and Episurf is now protecting a novel solution to facilitate ankle surgery”, comments Katarina Flodström, CRO & Head of IP, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.00 CET on 11 March 2019.
Tags: